Stem Cell Therapy to Treat Parkinson's Disease| Dr. David Greene Arizona

A neurological condition called Parkinson's disease is characterized by increasingly severe pain. It affects about 1% of seniors 60 years or older in industrialized nations. Reliable Source Experts like Dr. David Greene Arizona believe that inherited and environmental factors may be involved, even if the exact cause of the condition remains unknown. Dopamine levels decrease due to Parkinson's disease-related neuronal death in particular brain areas. Dopamine is a neurotransmitter. Brain cells emit dopamine to communicate with other nearby cells. When dopamine activity is decreased, these Parkinson's symptoms are among them:

Tremors Slowness Rigidity Gait Disturbance There is no recognized treatment for Parkinson's disease. However, experts like Dr. David Greene Arizona have recently investigated stem cell therapy to offer new therapeutic options. Keep reading for more information on current and upcoming developments in stem cell therapy for Parkinson's disease. Multiple approaches to using stem cells to treat Parkinson's disease are being researched.

The goal is to directly inject stem cells into the damaged areas of the brain, where they will mature into brain cells. The condition's symptoms should be lessened by these new brain cells' regulation of dopamine levels. It's essential to remember that researchers do not believe this would be a treatment for Parkinson's, only a possible cure.

Even if stem cell therapy could replace the destroyed brain cells, Parkinson's disease would remain. Parkinson's syndrome would probably eventually eradicate the grafted stem cells. It is still unknown whether stem cell therapy could be repeated to prevent Parkinson's disease symptoms from worsening or if the result would stay the same.

What have clinical trials found?

Before developing the technique for creating iPSCs, the only stem cell therapy for Parkinson's disease involved embryonic stem cells. However, this created moral and practical issues, which made the research process more challenging. Since iPSCs were made available, stem cells have been used in clinical trials for disorders involving brain damage, with largely unreliable results.

Trials have shown improvement in both movement problems and non-motor symptoms, such as bladder control. There are various challenges in the stem cell's place of origin. Using stem cells is comparable to transplanting an organ. For instance, if the iPSCs were taken from a donor, you might need to take immunosuppressant drugs to prevent your body from rejecting them. iPSCs created from your cells might be less likely to be rejected by your body.

However, experts believe that this will delay stem cell therapy while the iPSCs are being developed in the lab. In addition, this will be more expensive than a donor's validated, proven line of iPSCs.

What will the further generation of clinical trials focus on?

There are several Parkinson's disease symptoms. As a result, the Movement Disorder Society's MDS-UPDRS, an updated version of the Unified Parkinson's Disease Rating Scale (UPDRS), is widely used to assess them. Today's clinical trials aim to significantly increase individuals with Parkinson's disease's UPDRS or MDS-UPDRS scores. New delivery methods, such as intravenous or topical therapies, are being investigated in certain trials. Others are attempting to determine the maximum number of safe, effective doses.

The general safety of using innovative medical devices in stem cell therapy is also evaluated in other investigations. This area is still being researched. However, future research by specialists like Dr. David Greene Arizona will help to identify the most secure and effective approach to Parkinson's stem cell therapy.

Takeaway

The objective of stem cell therapy for Parkinson's disease is to replace harmed brain cells with fresh, undifferentiated stem cells. As they mature into brain cells, these stem cells may then control your dopamine levels. This can dramatically lessen several Parkinson's disease symptoms, according to doctors.

This medication is still being tested in the clinical setting. However, many proposed research are either currently underway or are actively seeking participants. The outcomes of these trials will determine how quickly stem cell therapy as a treatment for Parkinson's disease might become widely available.

Conclusion:

Dr. David Greene Arizona, a stem cell researcher, is working to provide experimental treatments for patients with serious ailments. For example, he demonstrates how doctors have treatments to help you manage your Parkinson's symptoms.